Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 04 04:00PM ET
104.78
Dollar change
+2.54
Percentage change
2.48
%
IndexRUT P/E45.33 EPS (ttm)2.31 Insider Own2.36% Shs Outstand18.27M Perf Week7.61%
Market Cap1.91B Forward P/E16.61 EPS next Y6.31 Insider Trans-18.40% Shs Float17.84M Perf Month1.58%
Income42.14M PEG3.02 EPS next Q1.34 Inst Own96.11% Short Float5.48% Perf Quarter20.60%
Sales133.48M P/S14.34 EPS this Y-11.41% Inst Trans4.38% Short Ratio8.18 Perf Half Y34.40%
Book/sh42.82 P/B2.45 EPS next Y16.96% ROA5.19% Short Interest0.98M Perf Year79.63%
Cash/sh12.42 P/C8.44 EPS next 5Y15.00% ROE5.85% 52W Range49.24 - 112.12 Perf YTD46.71%
Dividend Est.- P/FCF42.27 EPS past 5Y-13.18% ROI5.39% 52W High-6.55% Beta1.02
Dividend TTM- Quick Ratio15.70 Sales past 5Y-3.89% Gross Margin67.15% 52W Low112.79% ATR (14)3.35
Dividend Ex-DateJul 02, 2010 Current Ratio16.82 EPS Y/Y TTM53.74% Oper. Margin5.98% RSI (14)57.27 Volatility3.71% 3.01%
Employees58 Debt/Eq0.01 Sales Y/Y TTM-28.55% Profit Margin31.57% Recom1.14 Target Price125.57
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-2328.72% Payout0.00% Rel Volume0.61 Prev Close102.24
Sales Surprise25.71% EPS Surprise32.55% Sales Q/Q57.52% EarningsAug 06 AMC Avg Volume119.45K Price104.78
SMA202.97% SMA502.02% SMA20024.03% Trades Volume72,546 Change2.48%
Date Action Analyst Rating Change Price Target Change
Oct-03-24Initiated Oppenheimer Outperform $135
Jul-30-24Initiated RBC Capital Mkts Outperform $130
Apr-14-21Resumed Stephens Overweight $200
Feb-04-21Reiterated H.C. Wainwright Buy $229 → $310
Oct-06-20Initiated Barclays Overweight $156
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
Sep-06-24 09:20AM
Aug-20-24 09:00AM
Aug-06-24 04:01PM
Jul-24-24 06:30AM
Jul-23-24 04:01PM
07:00AM Loading…
Jul-08-24 07:00AM
Jul-01-24 08:00AM
Jun-27-24 08:00AM
Jun-18-24 08:00AM
Jun-14-24 12:00PM
Jun-06-24 11:31AM
Jun-04-24 09:55AM
08:50AM
May-23-24 04:59PM
May-20-24 06:00AM
12:00PM Loading…
May-13-24 12:00PM
May-10-24 08:50AM
May-09-24 09:40AM
May-08-24 01:22PM
12:19PM
May-07-24 09:01PM
05:40PM
04:00PM
11:29AM
07:30AM
Apr-23-24 08:31AM
Apr-17-24 09:55AM
Apr-08-24 08:15AM
Apr-05-24 06:00PM
Apr-04-24 09:30AM
09:00AM Loading…
09:00AM
Apr-03-24 09:00AM
Apr-01-24 06:15PM
Mar-28-24 11:30AM
Mar-26-24 06:15PM
Mar-21-24 09:00AM
Mar-20-24 06:00PM
Mar-19-24 09:30AM
Mar-14-24 06:00PM
Mar-07-24 09:00AM
Mar-05-24 04:01PM
Mar-04-24 08:00AM
Feb-29-24 09:30AM
Feb-28-24 07:34AM
Feb-27-24 07:00AM
Feb-22-24 04:01PM
Feb-16-24 08:00AM
Feb-13-24 04:01PM
Feb-01-24 05:00PM
Jan-10-24 07:30PM
Jan-05-24 04:30PM
Dec-12-23 12:01PM
09:00AM
09:00AM
Dec-11-23 09:00AM
Dec-06-23 04:02PM
Dec-01-23 08:20AM
Nov-28-23 09:01AM
Nov-09-23 04:47PM
Nov-08-23 04:01PM
Nov-06-23 09:00AM
Nov-01-23 08:00AM
Oct-25-23 04:01PM
Oct-18-23 08:00AM
Oct-09-23 06:15PM
Oct-03-23 06:00PM
Oct-02-23 09:00AM
09:00AM
Sep-27-23 09:00AM
Sep-26-23 05:05PM
Sep-22-23 09:00AM
Sep-21-23 09:20AM
Sep-18-23 05:17PM
Sep-01-23 10:02PM
Aug-08-23 04:01PM
Jul-27-23 01:30PM
Jul-25-23 04:30PM
Jul-17-23 08:59AM
08:45AM
Jun-29-23 09:00AM
Jun-21-23 08:00PM
Jun-09-23 09:40AM
Jun-06-23 11:40AM
11:10AM
Jun-05-23 11:49AM
09:01AM
Jun-02-23 12:39PM
12:35PM
Jun-01-23 11:29AM
May-30-23 07:01PM
May-25-23 05:00PM
May-24-23 09:55AM
09:40AM
May-17-23 01:59PM
08:07AM
May-16-23 09:56AM
07:30AM
07:00AM
May-12-23 12:08PM
11:34AM
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reardon AndrewCLO & SecretarySep 23 '24Option Exercise52.272,000104,54024,534Sep 25 08:54 PM
Reardon AndrewCLO & SecretarySep 23 '24Sale99.602,000199,20122,534Sep 25 08:54 PM
Espinoza OctavioChief Financial OfficerSep 20 '24Sale103.941,275132,51824,610Sep 24 07:41 PM
Korenberg Matthew EPresident & COOSep 23 '24Option Exercise52.729,772515,22760,549Sep 24 07:41 PM
Korenberg Matthew EPresident & COOSep 20 '24Option Exercise49.994,982249,05057,052Sep 24 07:41 PM
Korenberg Matthew EPresident & COOSep 23 '24Sale101.229,772989,12150,777Sep 24 07:41 PM
Korenberg Matthew EPresident & COOSep 20 '24Sale104.106,275653,23850,777Sep 24 07:41 PM
Reardon AndrewOfficerSep 23 '24Proposed Sale99.602,000199,201Sep 23 05:30 PM
Korenberg Matthew EOfficerSep 23 '24Proposed Sale101.5014,4371,465,403Sep 23 05:27 PM
Korenberg Matthew EOfficerSep 20 '24Proposed Sale104.106,275653,238Sep 20 06:12 PM
Espinoza OctavioOfficerSep 20 '24Proposed Sale103.941,275132,518Sep 20 05:39 PM
Espinoza OctavioChief Financial OfficerSep 17 '24Option Exercise79.631,486118,32825,885Sep 19 05:50 PM
Korenberg Matthew EPresident & COOSep 16 '24Option Exercise58.495,774337,69654,008Sep 18 07:55 PM
Espinoza OctavioChief Financial OfficerAug 28 '24Option Exercise66.5275350,08624,399Aug 30 09:00 PM
Reardon AndrewCLO & SecretaryAug 28 '24Option Exercise52.271,50078,40524,034Aug 30 08:56 PM
Reardon AndrewCLO & SecretaryAug 28 '24Sale106.391,500159,59122,534Aug 30 08:56 PM
Reardon AndrewOfficerAug 28 '24Proposed Sale106.391,500159,590Aug 28 04:39 PM
Korenberg Matthew EPresident & COOAug 26 '24Sale105.6111,3891,202,83149,510Aug 26 08:15 PM
Korenberg Matthew EPresident & COOAug 23 '24Sale104.806,312661,47960,899Aug 26 08:15 PM
Korenberg Matthew EPresident & COOAug 22 '24Sale105.541,157122,11067,211Aug 26 08:15 PM
Korenberg Matthew EOfficerAug 22 '24Proposed Sale105.0318,8581,980,567Aug 22 06:05 PM
Korenberg Matthew EPresident & COOAug 09 '24Sale98.5018,2451,797,13268,368Aug 13 05:21 PM
Davis Todd CChief Executive OfficerAug 08 '24Buy97.392,500243,480123,010Aug 09 05:52 PM
Korenberg Matthew EOfficerAug 09 '24Proposed Sale98.5018,2451,797,132Aug 09 05:16 PM
Gray Nancy RyanDirectorMay 09 '24Sale83.2093477,7135,633May 17 08:00 PM
Espinoza OctavioChief Financial OfficerMay 17 '24Option Exercise55.716,917385,34628,535May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 15 '24Sale86.015,873505,14823,882May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 17 '24Sale86.665,156446,84423,379May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 16 '24Sale86.002,264194,71221,618May 17 07:59 PM
Korenberg Matthew EPresident & Chief OperatingMay 14 '24Sale85.1014,1581,204,91286,263May 15 07:34 PM
Korenberg Matthew EPresident & Chief OperatingMay 13 '24Sale84.543,440290,828100,421May 15 07:34 PM
Reardon AndrewChief Legal Officer &May 09 '24Option Exercise52.2710,000522,70032,205May 13 05:32 PM
Reardon AndrewChief Legal Officer &May 09 '24Sale83.0410,000830,44922,205May 13 05:32 PM
Aryeh JasonDirectorApr 30 '24Option Exercise52.302,406125,83476,828May 02 06:07 PM
KOZARICH JOHN WDirectorApr 24 '24Option Exercise39.352,893113,84042,523Apr 26 06:35 PM
Davis Todd CChief Executive OfficerMar 25 '24Option Exercise57.3916,015919,147120,160Mar 27 05:47 PM
Sabba Stephen LDirectorMar 05 '24Option Exercise0.002,893030,819Mar 07 01:27 PM
Sabba Stephen LDirectorMar 05 '24Sale74.301,893140,65028,926Mar 07 01:27 PM
Aryeh JasonDirectorMar 05 '24Option Exercise39.352,893113,84074,422Mar 06 05:28 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Option Exercise56.621,26471,56429,895Feb 29 06:50 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Sale88.4614012,38429,755Feb 29 06:50 PM